PACE-CME

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

LDLc lowering with twiceayear injection of siRNA against PCSK The ORION trial
RestartResume
10' education - Sep. 16, 2019 - Prof. John Kastelein
  • Overview

    ESC 2019 Prof. John Kastelein shares the results of the phase 3 ORION-11 trial with inclisiran in ASCVD and risk equivalent patients not at LDL-C goal.

  • Educational information

    This video was recorded at ESC 2019 in Paris, France, on September 2, 2019.

  • Faculty

    Prof. John Kastelein, MD – Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he held the Strategic Chair of Genetics of Cardiovascular Disease.

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

    Read our news article on the ORION-11 trial

    The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free